Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(9):1405–1412. doi: 10.1038/bjc.1998.233

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

G P Adams 1, R Schier 1, A M McCall 1, R S Crawford 1, E J Wolf 1, L M Weiner 1, J D Marks 1
PMCID: PMC2150193  PMID: 9652755

Abstract

Single-chain Fv (scFv) molecules exhibit highly specific tumour-targeting properties in tumour-bearing mice. However, because of their smaller size and monovalent binding, the quantities of radiolabelled scFv retained in tumours limit their therapeutic applications. Diabodies are dimeric antibody-based molecules composed of two non-covalently associated scFv that bind to antigen in a divalent manner. In vitro, diabodies produced from the anti-HER2/neu (c-erbB-2) scFv C6.5 displayed approximately 40-fold greater affinity for HER2/neu by surface plasmon resonance biosensor measurements and significantly prolonged association with antigen on the surface of SK-OV-3 cells (t1/2 cell surface retention of > 5 h vs 5 min) compared with C6.5 scFv. In SK-OV-3 tumour-bearing scid mice, radioiodinated C6.5 diabody displayed a highly favourable balance of quantitative tumour retention and specificity. By as early as 4 h after i.v. administration, significantly more diabody was retained in tumour (10 %ID g(-1)) than in blood (6.7 %ID ml(-1)) or normal tissue (liver, 2.8 %ID g(-1); lung, 7.1 %ID g(-1); kidney, 5.2 %ID g(-1)). Over the next 20 h, the quantity present in blood and most tissues dropped approximately tenfold, while the tumour retained 6.5 %ID g(-1) or about two-thirds of its 4-h value. In contrast, the 24-h tumour retention of radioiodinated C6.5 scFv monomer was only 1 %ID g(-1). When diabody retentions were examined over the course of a 72-h study and cumulative area under the curve (AUC) values were determined, the resulting tumor-organ AUC ratios were found to be superior to those previously reported for other monovalent or divalent scFv molecules. In conclusion, the diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has promise as a delivery vehicle for therapeutic agents.

Full text

PDF
1405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. P., McCartney J. E., Tai M. S., Oppermann H., Huston J. S., Stafford W. F., 3rd, Bookman M. A., Fand I., Houston L. L., Weiner L. M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993 Sep 1;53(17):4026–4034. [PubMed] [Google Scholar]
  2. Allred D. C., Clark G. M., Molina R., Tandon A. K., Schnitt S. J., Gilchrist K. W., Osborne C. K., Tormey D. C., McGuire W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep;23(9):974–979. doi: 10.1016/0046-8177(92)90257-4. [DOI] [PubMed] [Google Scholar]
  3. Beaumier P. L., Krohn K. A., Carrasquillo J. A., Eary J., Hellström I., Hellström K. E., Nelp W. B., Larson S. M. Melanoma localization in nude mice with monoclonal Fab against p97. J Nucl Med. 1985 Oct;26(10):1172–1179. [PubMed] [Google Scholar]
  4. Begent R. H., Verhaar M. J., Chester K. A., Casey J. L., Green A. J., Napier M. P., Hope-Stone L. D., Cushen N., Keep P. A., Johnson C. J. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med. 1996 Sep;2(9):979–984. doi: 10.1038/nm0996-979. [DOI] [PubMed] [Google Scholar]
  5. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J. T., Dodge R., Clarke-Pearson D. L., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 1;50(13):4087–4091. [PubMed] [Google Scholar]
  6. Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S., Whitlow M. Single-chain antigen-binding proteins. Science. 1988 Oct 21;242(4877):423–426. doi: 10.1126/science.3140379. [DOI] [PubMed] [Google Scholar]
  7. Breitling F., Dübel S., Seehaus T., Klewinghaus I., Little M. A surface expression vector for antibody screening. Gene. 1991 Aug 15;104(2):147–153. doi: 10.1016/0378-1119(91)90244-6. [DOI] [PubMed] [Google Scholar]
  8. Colcher D., Bird R., Roselli M., Hardman K. D., Johnson S., Pope S., Dodd S. W., Pantoliano M. W., Milenic D. E., Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst. 1990 Jul 18;82(14):1191–1197. doi: 10.1093/jnci/82.14.1191. [DOI] [PubMed] [Google Scholar]
  9. Earp H. S., Dawson T. L., Li X., Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995 Jul;35(1):115–132. doi: 10.1007/BF00694752. [DOI] [PubMed] [Google Scholar]
  10. Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989 Oct 15;49(20):5656–5663. [PubMed] [Google Scholar]
  11. Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991 Sep 1;51(17):4575–4580. [PubMed] [Google Scholar]
  12. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444–6448. doi: 10.1073/pnas.90.14.6444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hu S., Shively L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y., Shively J. E., Wu A. M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996 Jul 1;56(13):3055–3061. [PubMed] [Google Scholar]
  14. Huston J. S., George A. J., Adams G. P., Stafford W. F., Jamar F., Tai M. S., McCartney J. E., Oppermann H., Heelan B. T., Peters A. M. Single-chain Fv radioimmunotargeting. Q J Nucl Med. 1996 Sep;40(3):320–333. [PubMed] [Google Scholar]
  15. Huston J. S., Levinson D., Mudgett-Hunter M., Tai M. S., Novotný J., Margolies M. N., Ridge R. J., Bruccoleri R. E., Haber E., Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(16):5879–5883. doi: 10.1073/pnas.85.16.5879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jain R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990 Feb 1;50(3 Suppl):814s–819s. [PubMed] [Google Scholar]
  17. Juweid M., Neumann R., Paik C., Perez-Bacete M. J., Sato J., van Osdol W., Weinstein J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992 Oct 1;52(19):5144–5153. [PubMed] [Google Scholar]
  18. Jönsson U., Fägerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Löfås S., Persson B., Roos H., Rönnberg I. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 1991 Nov;11(5):620–627. [PubMed] [Google Scholar]
  19. Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchko G. M. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993 Aug 12;329(7):459–465. doi: 10.1056/NEJM199308123290703. [DOI] [PubMed] [Google Scholar]
  20. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods. 1991 Dec 15;145(1-2):229–240. doi: 10.1016/0022-1759(91)90331-9. [DOI] [PubMed] [Google Scholar]
  21. King C. R., Kraus M. H., Aaronson S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985 Sep 6;229(4717):974–976. doi: 10.1126/science.2992089. [DOI] [PubMed] [Google Scholar]
  22. Kraus M. H., Popescu N. C., Amsbaugh S. C., King C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987 Mar;6(3):605–610. doi: 10.1002/j.1460-2075.1987.tb04797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Laub P. B., Gallo J. M. NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci. 1996 Apr;85(4):393–395. doi: 10.1021/js9503744. [DOI] [PubMed] [Google Scholar]
  24. Marks J. D., Hoogenboom H. R., Bonnert T. P., McCafferty J., Griffiths A. D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 5;222(3):581–597. doi: 10.1016/0022-2836(91)90498-u. [DOI] [PubMed] [Google Scholar]
  25. Milenic D. E., Yokota T., Filpula D. R., Finkelman M. A., Dodd S. W., Wood J. F., Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991 Dec 1;51(23 Pt 1):6363–6371. [PubMed] [Google Scholar]
  26. Molthoff C. F., Pinedo H. M., Schlüper H. M., Nijman H. W., Boven E. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br J Cancer. 1992 May;65(5):677–683. doi: 10.1038/bjc.1992.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pack P., Kujau M., Schroeckh V., Knüpfer U., Wenderoth R., Riesenberg D., Plückthun A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) 1993 Nov;11(11):1271–1277. doi: 10.1038/nbt1193-1271. [DOI] [PubMed] [Google Scholar]
  28. Pack P., Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 1992 Feb 18;31(6):1579–1584. doi: 10.1021/bi00121a001. [DOI] [PubMed] [Google Scholar]
  29. Perisic O., Webb P. A., Holliger P., Winter G., Williams R. L. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 1994 Dec 15;2(12):1217–1226. doi: 10.1016/s0969-2126(94)00123-5. [DOI] [PubMed] [Google Scholar]
  30. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993 Oct 21;329(17):1219–1224. doi: 10.1056/NEJM199310213291702. [DOI] [PubMed] [Google Scholar]
  31. Schier R., Marks J. D., Wolf E. J., Apell G., Wong C., McCartney J. E., Bookman M. A., Huston J. S., Houston L. L., Weiner L. M. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May;1(1):73–81. doi: 10.1016/1380-2933(95)00007-0. [DOI] [PubMed] [Google Scholar]
  32. Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., Crawford R. S., Weiner L. M., Marks C., Marks J. D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 8;263(4):551–567. doi: 10.1006/jmbi.1996.0598. [DOI] [PubMed] [Google Scholar]
  33. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  34. Stein R., Blumenthal R., Sharkey R. M., Goldenberg D. M. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts. Cancer. 1994 Feb 1;73(3 Suppl):816–823. doi: 10.1002/1097-0142(19940201)73:3+<816::aid-cncr2820731311>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  35. Wallasch C., Weiss F. U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995 Sep 1;14(17):4267–4275. doi: 10.1002/j.1460-2075.1995.tb00101.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ward E. S., Güssow D., Griffiths A. D., Jones P. T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989 Oct 12;341(6242):544–546. doi: 10.1038/341544a0. [DOI] [PubMed] [Google Scholar]
  37. Weiner L. M., Holmes M., Richeson A., Godwin A., Adams G. P., Hsieh-Ma S. T., Ring D. B., Alpaugh R. K. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol. 1993 Sep 1;151(5):2877–2886. [PubMed] [Google Scholar]
  38. Wolff E. A., Schreiber G. J., Cosand W. L., Raff H. V. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res. 1993 Jun 1;53(11):2560–2565. [PubMed] [Google Scholar]
  39. Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., Yoshida T., Terada M., Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene. 1988 Mar;2(3):283–287. [PubMed] [Google Scholar]
  40. Yorke E. D., Beaumier P. L., Wessels B. W., Fritzberg A. R., Morgan A. C., Jr Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Int J Rad Appl Instrum B. 1991;18(8):827–835. doi: 10.1016/0883-2897(91)90090-8. [DOI] [PubMed] [Google Scholar]
  41. van de Vijver M., van de Bersselaar R., Devilee P., Cornelisse C., Peterse J., Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987 May;7(5):2019–2023. doi: 10.1128/mcb.7.5.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES